Dementia and Alzheimer Disease

Epilepsy

Migraine

Headache and Migraine

MS Advanced Practice Providers

Multiple Sclerosis

NMOSD

MS and Demyelinating Disorders

Parkinson Disease

Movement Disorders

Ataxia

Chronic Inflammatory Demyelinating Polyneuropathy

Muscular Dystrophy

Neuromuscular

Insomnia

Narcolepsy

Sleep Disorders

Stroke

News

Media

All Videos

Medical World News

Podcasts

Weekly Recap

Cure Connections

Insights

News Network

NeurologyLive Peer Exchange

Medcast Podcasts

Medcast Videos

Peers & Perspectives

Roundtable Discussions

Conferences

Conference Coverage

Conference Listing

CME/CE

Partners

Publications

NeurologyLive

Bridging the Gaps

International Journal of MS Care

Resources

Expert Authors

FDA News

Features

Fellows' Corner

Future Leaders in Neurology

Giants of Multiple Sclerosis

Interactive Tools

Live Events

Neurology Resources

Virtual Events

Subscribe

Videos

The epilepsy specialist and Cleveland Clinic’s Chief Research and Information Officer discussed the wide-spread applicability of scalp EEG and the potential for machine learning models to help predict epilepsy surgery outcomes. [WATCH TIME: 4 minutes]

Scalability of Scalp EEG as a Tool for Epilepsy Surgery Outcomes: Lara Jehi, MD, MHCDS

Articles

For more than a 2-year treatment period, 95% of patients reported taking at least 95% of their daily medications with zilucoplan.

Medication Compliance High With Self-Administered Ziluocoplan in Myasthenia Gravis

Over a 12-month treatment period, patients on deferiprone demonstrated decreased blood ferritin and hippocampal QSM but caused accelerated cognitive decline and increased regional brain atrophy.

Negative Effect of Deferiprone Points to Impact of Iron Lowering in Alzheimer Disease

The findings suggest that future phase 3 trials should explore the duration of pain relief and headache recurrence, with the goal of developing structured treatment guidelines for PTH.

Sumatriptan Demonstrates Therapeutic Potential in Post-Traumatic Headache in Phase 2 Pilot Study

Dean and chief academic officer at the University of Miami Miller School of Medicine.

The dean and chief academic officer at the University of Miami Miller School of Medicine discussed the university’s investment in computational biology to advance aging and neuroscience research. [WATCH TIME: 5 minutes]

Driving Innovation in Aging and Neurodegenerative Research: Henri Ford, MD, MHA 

Here's the latest multidisciplinary multiple sclerosis (MS) research from the International Journal of MS Care.

Research from IJMSC September 2024

William S. and Lois Stiles Edgerly Professor of Neurology and Professor of Immunobiology; Chair, Neurology; Neurologist-in-Chief, Yale New Haven Hospital

The William S. and Lois Stiles Edgerly Professor of Neurology at Yale School of Medicine talked about the ongoing evolution of multiple sclerosis diagnostic criteria and the importance of comprehensive testing to guide early intervention and improve outcomes. [WATCH TIME: 5 minutes]

Evolution of Multiple Sclerosis Diagnostic Criteria and the Role of Spinal Taps: David A. Hafler, MD, FANA

NeurologyLive is your direct connection to the latest neurology news and interviews with expert neurologists in multimedia formats.

About Us

Advisory Board

Editorial

Contact Us

Advertise

Contact MJH LS

Do Not Sell My Information

Terms and Conditions

Privacy

NeurologyLive – Clinical Neurology News and Neurology Expert Insights

Facebook

LinkedIN

YouTube

Spotlight

AANEM 2024

CTAD 2024

MDS 2024

Clinical Focus

Dementia/Alzheimer

Headache/Migraine

Video Series

1.125rem

Clinical

 Parkinson disease Disease Spotlight page gives readers key updates and detailed coverage on the most recent expert conversations and data presentations relevant to the treatment of the movement disorder.

Stuart Isaacson, MD, Rajesh Pahwa, MD, and Jennifer Goldman, MD discuss optimizing PD treatment with levodopa and adjunct therapies, addressing patient and pharmacologic challenges, coordinating care, and anticipating the impact of emerging therapies and upcoming Medicare Part D changes.

Stuart Isaacson, MD, Rajesh Pahwa, MD, and Jennifer Goldman, MD discuss optimizing PD treatment with levodopa and adjunct therapies, addressing patient and pharmacologic challenges, coordinating care, and anticipating the impact of emerging therapies and upcoming Medicare Part D changes.

Multisymptomatic Care in Parkinson's Disease

 is now live! Scroll down to listen, and make sure to subscribe on your favorite streaming service.

 features Dr. Anne Marie Morse, DO, a neurologist with special qualifications in child neurology and a sleep medicine specialist, best known for putting the DAMM in 

 and for always looking for digestible, actionable patient-directed sleep tips, tricks and tools to achieve optimal outcomes. Dr. Morse has joined forces with Brandon Hedgecock, DDS, D-ABDSM, a dentist and founder of Hedgecock Dental and 

; and Matthew Allard, AKA the "Sleep Connector," an experienced sleep professional with 20 years of experience helping others sleep and breathe better nightly, to break down the barriers between dentistry and medicine to develop educational content that considers the whole person and illustrate how sleep relates to lifestyle, wellness, and culture.

Sleeping Around the Podcast realized they had more to give and are a partner with 

Sleeping Around the Podcast × NeurologyLive

 for neurology-focused sleep content to allow any neurology stakeholder to add to their knowledge bank and skillset on how to use sleep as the diagnostic, prognostic, and therapeutic neurology tool it is designed to be.

 – Connection between PD and sleep disorders

 – Overview of study assessing biomarker for EDS in Parkinson disease

 – Role of neurofilament light chain in PD

– Patient demographics and differences of NfL increases 

. Check out the links below to subscribe on your preferred podcast platform.

Sleeping Around the Podcast

Sleeping Around the Podcast × NeurologyLive brings you a clinical overview of a newly published study highlighting extracellular vesicle-associated miRNA features that could be diagnostically informative of RBD in patients with Parkinson disease.

Sleeping Around the Podcast × NeurologyLive: Candidate Biomarkers to Detect REM Sleep Behavior Disorder in Parkinson Disease

Watch the video version of this episode here. 

Drs Isaacson, Pahwa, and Gupta discuss the management of dyskinesia and providing good ON time in Parkinson’s disease, sharing practical tips for early identification and treatment of dyskinesia, as well as their experience with current treatments.

Dyskinesia: Importance of Giving Patients More Good “On- Time" in Parkinson’s Disease

 – Sleep disturbances as major feature of PD

 – Parkinson-related pathological changes

Sleeping Around the Podcast × NeurologyLive brings you a scientific overview of the crossover between Parkinson disease and sleep disorders. 

Sleeping Around the Podcast × NeurologyLive: Parkinson Disease Awareness Month

To watch the full video episode, follow this link. 

Expert neurologists discuss strategies to widen the therapeutic window of Parkinson’s disease and options available to treat dyskinesia, providing better control of Parkinson’s disease.

Widening the Therapeutic Window in the Management of Parkinson’s Disease

 to subscribe on your favorite streaming service.

The Mind Moments podcast features exclusive interviews with leaders in the field discussing the latest research and disease management strategies across the breadth of neurology, including epilepsy, multiple sclerosis, Parkinson disease, dementia, sleep disorders, and more.

Episode 93, "Caring for Women With Parkinson Disease," features an exclusive interview with 

, an assistant professor of neurology and director of the Parkinson’s Disease & Movement Disorder Program at Global Neurosciences Institute, who spoke with us about the current landscape of care for women with Parkinson disease (PD), how the approach to their care can differ from men, the major gaps around education and treatment for these women, and much more.

, a streaming channel from MJH Life Sciences

. Check out new content and shows every day, only at

The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here:

FDA Issues Complete Response Letter to Amneal for Parkinson Agent IPX203

FDA Grants Traditional Approval to Lecanemab as Therapy for Early-Stage Alzheimer Disease

Medicare Expands Coverage for Fully Approved Alzheimer Agent Lecanemab

FDA Approves Image Guided Programming Software for Vercise Deep Brain Stimulation Systems

 – The presentation of Parkinson disease for women

 – Nonmotor symptoms that can create challenges  for diagnosis

 – OFF episodes and dyskinesia in women vs men

 – Being attentive to patient needs in treatment

 – The daily impact of Parkinson disease

 – Encouraging women with Parkinson to participate in trials

– Conversations in areas of limited knowledge

 to subscribe to the Mind Moments podcast. Be sure to leave a rating and review for the show. Thanks for listening!

Hoping to listen on your favorite podcast app? See below:

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Jill Farmer, DO, MPH. [LISTEN TIME: 28 minutes]

Episode 93: Caring for Women With Parkinson Disease

 podcast features exclusive interviews with leaders in the field discussing the latest research and disease management strategies across the breadth of neurology, including epilepsy, multiple sclerosis, Parkinson disease, dementia, sleep disorders, and more.

Episode 81, "Widening the Therapeutic Window in Parkinson Disease," features an exclusive interview with Robert A. Hauser, MD, MBA, director of the Parkinson’s and Movement Disorders Center at the University of South Florida. He spoke about the current state of therapeutics in Parkinson disease, some of the lingering challenges in day-to-day management, the promise of novel agents in development such as IPX203, and more.

This episode is brought to you by the Giants of Multiple Sclerosis®. This premier neuroscience award program celebrates pioneers, innovators, and future generations of leaders for their remarkable achievements in Multiple Sclerosis. 

Neurelis Files IND for Potentially First Therapy to Treat Cerebral Cavernous Malformations

CDC and FDA Announce Stroke Safety Concern Related to Pfizer-BioNTech Bivalent COVID-19 Vaccine

FDA Hands Eli Lilly Complete Response Letter for Donanemab After Lack of Long-Term Data

FDA Clears Trial Hold on Late-Onset Pompe Disease Gene Therapy AT845

Proclaim XR Spinal Cord Stimulation Wins Approval for Painful Diabetic Peripheral Neuropathy

 – Lingering unmet needs in Parkinson disease management

 – The advances in identifying therapeutic targets in PD

 – Bridging the gap to more effective long-term treatment

 – Overview of IPX203 and its potential to treat PD

 – Safety profile of IPX203 in clinical development

 – The importance of addressing dose-wearing off

 podcast. Be sure to leave a rating and review for the show. Thanks for listening!

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Robert A. Hauser, MD, MBA. [LISTEN TIME: 20 minutes]

Episode 81: Widening the Therapeutic Window in Parkinson Disease

Episode 78, "A Virtual Reality Platform for Parkison Disease," features an exclusive interview with Jay Alberts, PhD, the Edward F. and Barbara A. Bell Endowed Chair at Cleveland Clinic. He joined the show to discuss the complexities that come with understanding early signs of PD, and how the newly designed Cleveland Clinic Virtual Reality Shopping (CC-VRS) platform works towards that, among other topics.

. Check out new episodes of a variety of shows, airing every single day, only on

International Committee Proposes MS Disease Progression Framework Driven by Pathophysiological Mechanisms, Not Clinical Phenotype

Anti-Amyloid-ß Oligomer Antibody ACU193 Gains FDA Fast Track Designation

Duchenne Gene Therapy SRP-9001 Wins Priority Review

Lecanemab Represents Promising Therapy for Alzheimer Disease, Posts Positive Phase 3 Secondary Analyses

Donanemab Shows Greater Ability to Clear Amyloid Plaque Than Aducanumab

Episode Breakdown

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Jay Alberts, PhD. [LISTEN TIME: 27 minutes]

Episode 78: A Virtual Reality Platform for Parkinson Disease

At week 10, investigators observed no differences between triheptanoin and placebo on the frequency of movement disorder events in patients with Glut1 deficiency disorder.

Triheptanoin Shows No Significant Effect on Movement Disorder Events in Glut1 Deficiency Syndrome

The global, placebo-controlled, 12-week study aims to enroll 330 participants and expects topline results in the first half of 2026. 

Phase 3 ARISE Trial of Parkinson Therapy Solengepras Begins Dosing

According to the company, VQ-101 is the first small molecule to show over 75% activation of the lysosomal enzyme GCase in humans, with phase 1 results in healthy volunteers indicating tolerability and exposure levels that support once-daily dosing.

VQ-101 Show Promise in Interim Phase 1 Data for GBA-Parkinson Disease Treatment

After just 6 weeks of treatment, patients showed antibody levels 16 times higher than those in the placebo group, highlighting the vaccine’s potential to slow disease progression.

Parkinson Immunotherapy ACI-7104.056 Demonstrates Positive Antibody Responses in Phase 2 Trial Update

Initial findings showed significant improvements from baseline in the disease-specific, patient-reported quality of life scores in both the high and low dose AAV-GAD groups, with no significant change in the sham group at 26 weeks.

GAD-Related Parkinson Gene Therapy AAV-GAD Demonstrates Efficacy in Topline Findings 

Amanda Hare on StrivePD

"StrivePD empowers patients to focus on what brings them joy and quality of life. By tracking what they want to do but can’t, we can help them identify patterns and work together to reduce symptoms, making daily life more meaningful."

Parkinson disease (PD) is a multifactorial neurodegenerative disorder that affects approximately 10 million people worldwide. The disease, which is the second most common neurodegenerative disorder worldwide, is primarily managed through medications like levodopa and deep brain stimulation. To date, there are no FDA-approved treatments that target the underlying pathology of the disease; however, there has been improvements in the treatment optimization of available therapies to minimize effects of the disease.

One mobile device application, StrivePD, allows patients to track their symptoms over time, giving them greater insights on how medications and physical activity impact their daily functioning. Through the app, patients can learn from patterns in behaviors to manage their condition better, and set-up medication reminders for adherence. In addition, both clinicians and patients are able to view the symptom data in one place, allowing for improved communication and better understanding of patients’ well-being. Furthermore, through the app, patients may be able to participate in IRB-approved clinical trials for PD.

To learn more about the data collection StrivePD offers, and how it may be valuable to patients with PD, 

 sat down with Amanda Hare, DNP, a doctor of nursing practice specialized in movement disorders and medical science liaison at Rune Labs. In the interview, she stressed that the app allows user to log symptoms, daily activities, and medication adherence, creating personalized reports that help users and clinicians identify trends and adjust treatments for optimal daily functioning. Furthermore, she touched on the latest changes to the software, introducing an artificial intelligence-driven, auto-generated monthly reports, enabling over 10,000 users to see trends in symptoms, medication use, and activity.

The doctor of nursing practice specialized in movement disorders discussed specific data the StrivePD app captures and how it can enhance quality of life for patients with Parkinson disease. [WATCH TIME: 3 minutes]

Using Data Collection to Improve Parkinson Disease Treatment Personalization: Amanda Hare, DNP

"I’ve always thought we have unrealistic expectations of patients to remember all their symptoms and meds over months. StrivePD captures this data, helping them synthesize what’s been happening—beyond just recalling the past two weeks."

Parkinson disease (PD), a neurodegenerative disorder that affects nearly 10 million people worldwide, is typically managed through a combination of medications, lifestyle changes, and in some cases, surgical interventions. The cornerstone of treatment are medications that primarily target dopamine deficiency, as dopamine-producing neurons progressively degenerate in PD. Many clinicians consider PD a disease among diseases because, as it a type of motor symptoms disorder and a degenerative brain disease.

While there has been little movement in the approval of disease-modifying therapies for PD, there has been enhancements to the personalized care of the disease. A few years ago, the FDA cleared StrivePD, a free disease management application that passively collects daily resting tremor and dyskinesia data via Apple’s Movement Disorder API. Through StrivePD, patients may track their symptoms over time and gain greater insights on how medications and physical activity impact them.

Amanda Hare, DNP, a doctor of nursing practice specialized in movement disorders and medical science liaison at Rune Labs, recently sat down with 

 to discuss the build of StrivePD and some of the advantages it offers the PD community. Hare, who has spent the last 5 plus years working with patients with movement disorders, stressed how StrivePD helps patient visualize patterns and trends over time, enhancing both patient self-awareness and clinician insights. Furthermore, he commented that this real-time feedback strengthens the patient-provider relationship, allowing for personalized care adjustments and promoting patient engagement in their own disease management.

The doctor of nursing practice specialized in movement disorders provided clinical insight on how the StrivePD application empowers patients with Parkinson disease to track symptoms, medication, and daily activities using an iPhone and Apple Watch. [WATCH TIME: 3 minutes]

Therapeutic Advantages of StrivePD for Parkinson Disease Management: Amanda Hare, DNP

Lucia Ricciardi neuropsychiatric symptoms of PD

"It’s not the medication per se, but the increased load of dopamine in predisposed individuals that can trigger symptoms. We must be especially cautious in people with cognitive impairment, advanced disease, or older age, tailoring dopaminergic medication with these risk factors in mind."

The consultant neurologist and senior lecturer at St. Georges Hospital in London, explores the origins of common neuropsychiatric symptoms experienced by patients with Parkinson disease and how they may be exasperated. [WATCH TIME: 4 minutes]

Parkinson Disease

Latest News